A New Dawn for Dry AMD: LIGHTSITE III Published in Retina
The publication of the LIGHTSITE III trial in Retina marks a major milestone for photobiomodulation therapy in dry age-related macular degeneration (AMD).
Valeda® is the first non-invasive light therapy shown in a large randomised controlled trial to improve vision and significantly reduce disease progression in selected patients with dry AMD — offering genuine hope where treatment options have previously been very limited.
I have been providing Valeda® photobiomodulation treatment since September 2023, and after more than two years of audited clinical experience, our real-world results closely mirror those published in the LIGHTSITE III study in May 2026. This is extremely encouraging.
Of particular importance is the significant reduction — seen both in the published trial and in our own patients — in the development of new Geographic Atrophy (GA). It is the progression from dry, drusen-laden macular degeneration to Geographic Atrophy that leads to irreversible retinal damage and often a steady decline in vision over as little as 4–5 years.
Read the published LIGHTSITE III paper in Retina.
